This article is more than 5 years old. Information may no longer be current.

BMG Pharma launches Ialuxid gel in China for post-surgical wounds

BMG Pharma announced it has launched its proprietary Ialuxid gel in the People’s Republic of China for the treatment of post-surgical wounds.

Ialuxid gel, in the version approved in China, is a non-antibiotic microbial gel formulated to create a moist wound environment conducive to healing, especially suitable for post-surgical wounds, according to a company press release. Luqa Pharmaceuticals will distribute the product nationwide, the release stated.

The gel formulation includes hyaluronic acid, glycine and hydrogen peroxide and forms a protective film on the skin to prevent bacterial infections. It is registered in Europe for treating acne lesions, folliculitis, paronychia, Molluscum Contagiosum and impetigo, according to the release.

Reference: www.bmgpharma.com.